Company news
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) news
Every Dogwood Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
August 17, 2026
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
August 13, 2026
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
July 20, 2026
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
June 30, 2026
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
May 18, 2026
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
May 14, 2026
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
May 7, 2026
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $...
April 23, 2026
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain...
April 15, 2026
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 18, 2026
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
March 10, 2026
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
February 2, 2026
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
January 12, 2026
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15
December 30, 2025
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
December 22, 2025
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
December 2, 2025
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for Dece...
November 11, 2025
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
November 6, 2025
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 30, 2025
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
October 14, 2025
DWTX: Licenses SP16 for Treatment of Cancer Related Pain…
October 10, 2025
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at...
October 7, 2025
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Relate...
September 29, 2025
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
August 13, 2025
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
August 7, 2025
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
August 6, 2025
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
June 3, 2025
Dogwood Therapeutics Announces First Quarter 2025 Financial Results
May 8, 2025
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
May 1, 2025
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
April 11, 2025
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
April 3, 2025
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
March 31, 2025
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neur...
March 18, 2025
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq...
March 13, 2025
Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
March 12, 2025
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (C...
January 21, 2025
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator...
November 18, 2024
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
November 7, 2024
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
October 31, 2024
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 30, 2024
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 7, 2024
Virios Therapeutics Announces Second Quarter 2024 Financial Results
August 8, 2024
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
August 1, 2024
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
July 23, 2024
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COV...
May 22, 2024
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COV...
May 19, 2024
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 17, 2024
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
May 2, 2024